IP Verse

Fixed Drug Ratios For Treatment Of Hematopoietic Cancers And Proliferative Disorders - EP3300601

The patent EP3300601 was granted to Celator Pharmaceuticals on Jan 12, 2022. The application was originally filed on Feb 15, 2008 under application number EP17200498A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3300601

CELATOR PHARMACEUTICALS
Application Number
EP17200498A
Filing Date
Feb 15, 2008
Status
Granted And Under Opposition
Dec 10, 2021
Grant Date
Jan 12, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKOct 12, 2022ELKINGTON AND FIFEADMISSIBLE
SANDOZOct 11, 2022KRAUS & LEDERER PARTGMBBADMISSIBLE
STADA ARZNEIMITTELOct 11, 2022HAMM & WITTKOPPADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2007076117
OPPOSITIONUS2004152632
OPPOSITIONWO2005102359
OPPOSITIONWO2007076117
SEARCHUS2004152632
SEARCHWO2005102359
SEARCHWO2007076117

Non-Patent Literature (NPL) Citations (30) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- MAYER, L. D. et al., Mol. Cancer Ther., (20060000), vol. 5, pages 1854 - 1863-
DESCRIPTION- TALLUM et al., Blood, (20050000), vol. 106, page 2243-
EXAMINATION- Anonymous, "Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients", (20071210), URL: http://rxtimes.com/celatorr-pharmaceuticals-reports-cpx-351-shows-anti-cancer-activity-in-leukemia-patients/, (20200116), XP055658602-
EXAMINATION- ERIC J. FELDMAN ET AL, "Abstract", BLOOD, US, (20071116), vol. 110, no. 11, doi:10.1182/blood.V110.11.900.900, ISSN 0006-4971, pages 900 - 900, XP055658596
OPPOSITION- Anonymous, "Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients", (20071210), URL: http://rxtimes.com/celatorr-pharmaceuticals-reports-cpx-351-shows-anti-cancer-activity-in-leukemia-patients/, (20200116), XP055658602-
OPPOSITION- Anonymous, "History of Changes for Study: NCT00389428 Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer ", Clinicaf Trials.gov, (20120516), XP055974382-
OPPOSITION- "Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients", (20071210), URL: http://rxtimes.com/celatorr-pharmaceuticals-reports-cpx-351-shows-anti-cancer-activity-in-leukemia-patients/, XP055658602-
OPPOSITION- D48a: Curriculum Vitae of Barry Liboiron, Ph.D.-
OPPOSITION- D48: Expert Report of Barry Liboiron, Ph.D.-
OPPOSITION- Dicko, A. ; Kwak, S. ; Frazier, A.A. ; Mayer, L.D. ; Liboiron, B.D., "Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin", International Journal of Pharmaceutics, ELSEVIER, NL, NL , (20100531), vol. 391, no. 1-2, ISSN 0378-5173, pages 248 - 259, XP027018892-
OPPOSITION- Gregoriadis Gregory, "Fixed Drug Ratio Liposome Formulations of Combination Cancer Therapeutics ", Liposome Technology Third Edition , (20060912), pages 25 - 40, XP055974392-
OPPOSITION- H. SKAYNEH et al., "A critical review of animal models used in acute myeloid leukemia pathophysiology", Genes, (20190000), vol. 10, no. 614, pages 1 - 35, XP055974251-
OPPOSITION- J. KELL, "Treatment of relapsed acute myeloid leukaemia", Reviews on Recent Clinical Trials, (20060000), vol. 1, pages 103 - 111, XP055974210-
OPPOSITION- Johnstone Sharon A, Pierrot ;, Harvie, Kadhim Salam, Harasym Troy, Tardi Paul, Harasym Natashia, Mayer Lawrence, Metrics View, Crossref, "Cytarabine (Cyt):Daunorubicin (Daun) combined inside liposomes at a fixed synergistic ratio leads to potent therapeutic activity against a range of preclinical leukemia models", Proc Amer Assoc Cancer Res, (20060415), vol. 47, XP055974388-
OPPOSITION- Johnstone Sharon, Harvie Pierrot, Shew Clifford, Kadhim Salam, Harasym Troy, Tardi Paul, Harasym Natashia, Bally Marcel, Mayer Lawrence D, "1405 Synergistic antitumor activity observed for a fixed ratio liposome formulation ofCytarabine (Cyt):Daunorubicin (Daun) against preclinical leukemia models. ", Proceedings of the American Association for Cancer Research •, (20050401), vol. 46, XP055974385-
OPPOSITION- Johnstone S;, Harvie P; Shew C; Kadhim S; Harasym T; Tardi P; Harasym N; Bally M; Mayer L D, "Synergistic anti-tumor activity observed for a fixed ratio liposome formulation of cytarabine (Cyt): Daunorubicin (Daun) against preclinical leukemia models abstract 1405", American Association for Cancer Research (AACR, (20050101), XP055974387-
OPPOSITION- Johnstone, S.; Harvie, P.; Shew, C.; Kadhim, S.; Harasym, T.; Tardi, P.; Harasym, N.; Bally, M.; Mayer, L.D., "Synergistic anti-tumor activity observed for a fixed ratio liposome formulation of cytarabine (Cyt): Daunorubicin (Daun) against preclinical leukemia models", American Association for Cancer Research. Proceedings of the Annual Meeting, American Association for Cancer Research, US, US , (20050101), vol. 46, ISSN 0197-016X, page Abstr. 1405, XP009130722-
OPPOSITION- Johnstone S; Harvie P; Shew C; Kadhim S; Harasym T; Tardi P; Harasym N; Bally M; Mayer L D, "Synergistic antitumor activity observed for a fixed ratio liposome formulation of Cytarabine (Cyt):Daunorubicin (Daun) against preclinical leukemia models", Proc. Amer. Assoc. Cancer Res., (20050000), page 46, XP009130722-
OPPOSITION- Prakash S, "Carrier-mediated and artificial-cell targeted cancer drug delivery", Artificial cells, cell engineering and therapy, (20070531), pages 472 - 478, XP055974393-
OPPOSITION- W.R. SPERR et al., "A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2x1 g/m2 on days 1, 2, 3, and 5)", Clin. Cancer Res, (20040000), vol. 10, pages 3965 - 3971, XP055974260-
OPPOSITION- E. MCCORMACK et al., "Animal models of acute myelogenous leukaemia - development, application and future perspectives", Leukemia, (20050000), vol. 19, doi:10.1038/sj.leu.2403670, pages 687 - 706, XP037782292
OPPOSITION- L.D. MAYER et al., "Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice", Mol. Cancer. Ther., (20060000), vol. 5, no. 7, pages 1854 - 1863, XP002427287
OPPOSITION- MAYER L D et al., "Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice", Molecular Cancer Therapeutic s, (20060000), vol. 5, no. 7, doi:10.1158/1535-7163.MCT-06-0118, pages 1854 - 1863, XP002427287
OPPOSITION- Mayer L D, ET AL, "Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20060701), vol. 5, no. 7, doi:10.1158/1535-7163.MCT-06-0118, ISSN 1535-7163, pages 1854 - 1863, XP002427287
OPPOSITION- FELDMAN E J et al., "Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS).", Blood, (20071116), vol. 110, no. 11, page 900, XP055658596
OPPOSITION- FELDMAN, E.J. et al., "Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS).",", Blood, Atlanta, Georgia, (20071208), vol. 110, no. 11, XP055658596
OPPOSITION- Feldman Eric J; Lancet Jeffrey E; Kolitz Jonathan E; Asatiani Ekatherine; Curcio Tania J; Burton Michelle K; Fricano Marjorie; Begley Amanda R; Swenson Christine; Mayer Lawrence; Janoff Andrew S; Louie Arthur C, "Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS)", Blood, (20070000), vol. 110, no. 11, pages 274a - 275a, XP086649726
OPPOSITION- Batist G., Chi K., Miller W., Chia S., Hasanbasic F., Fisic A., Mayer L., Swenson C., Janoff A., Gelmon K., "Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan (IRI) and floxuridine (FLOX), in patients with advanced solid tumors", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20060620), vol. 24, no. 18_suppl, doi:10.1200/jco.2006.24.18_suppl.2014, ISSN 0732-183X, pages 2014 - 2014, XP055974390
SEARCH- JOHNSTONE S ET AL, "Synergistic anti-tumor activity observed for a fixed ratio liposome formulation of cytarabine (Cyt): Daunorubicin (Daun) against preclinical leukemia models", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, (20050101), vol. 46, ISSN 0197-016X, XP009130722 [A] 1-15 * the whole document *-
SEARCH- MAYER L D ET AL, "Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice", MOLECULAR CANCER THERAPEUTICS, (20060701), vol. 5, no. 7, pages 1854 - 1863, XP002427287 [I] 1-15 * page 1860 - page 1861 * * abstract * [Y] 1-15

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents